Welcome to our dedicated page for Rxsight news (Ticker: RXST), a resource for investors and traders seeking the latest updates and insights on Rxsight stock.
RxSight, Inc. develops and sells ophthalmic medical technology for customized vision after cataract surgery. Its RxSight Light Adjustable Lens system includes Light Adjustable Lens products, the Light Delivery Device and related accessories, enabling post-operative adjustment of an intraocular lens based on patient visual feedback.
RxSight news commonly covers financial results, sales guidance, Light Adjustable Lens unit demand, Light Delivery Device placements and installed-base growth. Company updates also address clinical evidence presented in cataract and refractive surgery forums, regulatory approvals in international markets, healthcare conference participation and executive finance leadership changes.
RxSight, Inc. (NASDAQ: RXST), a medical device company focused on enhancing vision after cataract surgery, announced participation in the Needham Virtual Healthcare Conference. Management will present on April 11, 2022, at 12:45 PM PT / 3:45 PM ET. The presentation can be accessed live and archived via the company’s website. RxSight is known for its Light Adjustable Lens (LAL) system, the first IOL technology allowing doctors to customize visual acuity post-surgery, which now includes ActivShield™ technology for UV protection.
RxSight, Inc. (NASDAQ: RXST) reported significant financial growth for Q4 2021, achieving $8.4 million in revenue, a 71% increase year-over-year. The fiscal year 2021 revenue totaled $22.6 million, up 54% from 2020. The company sold 45 Light Delivery Devices and 2,959 Light Adjustable Lenses in Q4 alone. Despite this growth, operating expenses surged by 81% to $17.5 million, resulting in a net loss of $(15.7) million for Q4. Looking ahead, RxSight projects 2022 revenue between $40.0 million and $44.0 million.
RxSight, Inc. (NASDAQ: RXST) announced it will release its financial results for the fourth quarter and fiscal year 2021 on March 8, 2022, after market close. A conference call with management will follow at 1:30 p.m. PT to discuss the results. The company specializes in ophthalmic medical devices aimed at enhancing post-cataract surgery vision through its innovative Light Adjustable Lens (LAL) system. This technology includes unique features like ActivShield™ for UV protection.
RxSight, Inc., an ophthalmic medical device company based in Aliso Viejo, California, has announced participation in the SVB Leerink Global Healthcare Conference. Management will join a fireside chat on February 17, 2022, at 12:40 PM PT / 3:40 PM ET. Interested audiences can access the live or archived webcast via the company's investor section. RxSight is recognized for its innovative Light Adjustable Lens system, which allows customization of visual acuity post-cataract surgery, now enhanced with ActivShield technology for UV protection.
RxSight, Inc. (NASDAQ: RXST) reported preliminary unaudited financial results for Q4 and the fiscal year 2021. Q4 revenue is expected to be about $8.4 million, up 71% year-over-year, driven by sales of 45 Light Delivery Devices (LDD™s) and 2,959 Light Adjustable Lenses (LAL®s). Fiscal year 2021 revenue is projected at $22.6 million, reflecting 54% growth. The installed base reached 206 LDDs. As of December 31, 2021, cash and equivalents totaled $159.3 million. The company anticipates continued growth in 2022, pending the completion of its audit.
On January 4, 2022, RxSight (NASDAQ: RXST) announced the appointment of Tamara R. Fountain, M.D. and Shweta Singh Maniar to its Board of Directors. The board chair, J. Andy Corley, highlighted their extensive healthcare leadership experience, which is expected to support the strategic growth of the company and enhance its Light Adjustable Lens system for post-cataract surgery patients. Dr. Fountain is a noted ophthalmologist and past president of the American Academy of Ophthalmology, while Ms. Maniar brings significant expertise from her roles at Google Cloud and Genentech.
RxSight, Inc. (NASDAQ: RXST), a leader in ophthalmic medical devices, will participate in the virtual J.P. Morgan Healthcare Conference on January 13, 2022, at 6:45 am PT / 9:45 am ET. This presentation will focus on their innovative Light Adjustable Lens system, which customizes visual acuity post-cataract surgery. Additionally, the lens now includes ActivShield technology for UV protection. Interested parties can access the live stream via the company’s website.
RxSight, Inc. (NASDAQ: RXST) has announced its participation in the virtual Ophthalmology Day at BTIG, scheduled for November 30, 2021, at 8:30 am PT / 11:30 am ET. The event will feature a fireside chat with the company’s management, and interested parties can access a live and archived webcast via the company’s website.
Specializing in ophthalmic medical devices, RxSight aims to enhance vision for cataract surgery patients with its innovative Light Adjustable Lens system, which includes ActivShield technology for UV protection.
RxSight, Inc. (NASDAQ: RXST) reported a strong third quarter in 2021, achieving revenue of $5.8 million, up 39% year-over-year and 18% sequentially. This growth was fueled by the sale of 31 Light Delivery Devices and 1,977 Light Adjustable Lenses. Gross profit increased to $1.3 million (23% of revenue), while operating expenses surged 50% to $14.5 million. The net loss for the quarter was $(12.7) million or $(0.68) per share. The company forecasts full-year 2021 revenue between $21.0 million and $21.4 million.
RxSight, Inc. announced it will report its third-quarter financial results on November 10, 2021, after market close. The management will discuss the results in a conference call scheduled for 1:30 p.m. PT / 4:30 p.m. ET. Investors can access the call via live webcast or by phone. RxSight focuses on innovative ophthalmic devices, specifically the Light Adjustable Lens system, which enhances visual acuity after cataract surgery. The product features ActivShield technology for UV protection.